Surmodics Reports Fourth Quarter Fiscal 2020 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020.
Summary of Fourth Quarter and Recent Highlights
Revenue of $22.5 million, a decrease of 27% year-over-year
GAAP EPS of ($0.22), non-GAAP EPS of ($0.18)
FDA clearance received for PounceTM Thrombus Retrieval System for non-surgi...